Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients

World Journal of Gastroenterology

Volumn 19, Issue 47, 2013, Pages 8924-8928

  Mangia, Alessandra ^a   Mottola, Leonardo ^a   Santoro, Rosanna ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Genotype 3; Hepatitis C virus; Interleukin 28B; Liver cirrhosis

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN;

ARTICLE; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

GENOTYPE 3; HEPATITIS C VIRUS; INTERLEUKIN 28B; LIVER CIRRHOSIS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84890913301     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i47.8924     Document Type: Article

References (26)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444 [PMID: 21898493 DOI: 10.1002/hep.24641]
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
3. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 10.1038/nature08463]
4. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/na-ture08309]
5. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109 [PMID: 19749757 DOI: 10.1038/ng.449]
6. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104 [PMID: 19749758 DOI: 10.1038/ng.447]
7. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Wit-teck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345. e1-7 [PMID: 20060832 DOI: 10.1053/j.gastro.2009.12.056]
8. Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchi-son J, Soriano V. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24: F23-F29 [PMID: 20389235 DOI: 10.1097/QAD.0b013e3283391d6d]
9. Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hell-strand K, Neumann AU, Lagging M. IL28B polymorphisms predict reduction of HCV RNA from the frst day of therapy in chronic hepatitis C. J Hepatol 2011; 55: 980-988 [PMID: 21354446 DOI: 10.1016/j.jhep.2011.01.050]
10. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827, 827.e1 [PMID: 20621700 DOI: 10.1053/j.gastro.2010.05.079]
11. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, Lötsch J, Berg T. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421 [PMID: 21112657 DOI: 10.1016/j.jhep.2010.07.041]
12. Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Bein-hardt S, Steindl-Munda P, Kerschner H, Kessler HH, Ferenci P. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with pe-ginterferon alfa-2a and ribavirin. J Hepatol 2011; 54: 866-871 [PMID: 21145807 DOI: 10.1016/j.jhep.2010.08.024]
13. Lindh M, Lagging M, Färkkilä M, Langeland N, Mørch K, Nilsson S, Norkrans G, Pedersen C, Buhl MR, Westin J, Hellstrand K. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-1752 [PMID: 21606533 DOI: 10.1093/infdis/ jir193]
14. Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754 [PMID: 21374656 DOI: 10.1002/hep.24154]
15. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassa-nein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
16. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13 [PMID: 21254157 DOI: 10.1002/hep.23976]
17. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Me-ta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment Pharmacol Ther 2012; 36: 91-103 [PMID: 22591106 DOI: 10.1111/j.1365-2036.2012.05131.x]
18. Rangnekar AS, Fontana RJ. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat 2013; 20: 377-384 [PMID: 23647954 DOI: 10.1111/jvh.12039]
19. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Forna-siere E, Pasino M, Ieluzzi D, Cussigh A, Cmet S, Pirisi M, Toniutto P. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepa-tology 2011; 53: 1118-1126 [PMID: 21480318 DOI: 10.1002/ hep.24201]
20. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Do-nato F, Negro F. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162-1172 [PMID: 21443535 DOI: 10.1111/j.1365-2036.2011.04635.x]
21. Mangia A, Francavilla R, Merola V, Barbarini G, Russello M, Lorenzo Nosotti L, Nicola Minerva N, Bacca D, Romano M, Cuccorese G, Montalto G, Agostinacchio E, De Luna A, Mariano C, Monti M, Pellicelli AM, Sogari F, Mottola L, Petruzzel-lis D, Piazzolla V, Ripoli M, Santoro R, Mecenate F. Benefit of weight based dosages of Ribavirin (RBV) in combination with PegInterferon (PegIFN) α2a in naïve patients with HCV2 and HCV3: results of an Italian Randomized Controlled Trial, the WRITE study. Hepatology 2012; 56: 1737
22. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchi-son JG. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011; 54: 772-780 [PMID: 21626525 DOI: 10.1002/hep.24458]
23. Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. Treatment with pegylated in-terferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-1265 [PMID: 15558712 DOI: 10.1002/hep.20467]
24. Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42 [PMID: 17975791 DOI: 10.1002/hep.21975]
25. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis 2008; 12: 713-726, xi [PMID: 18625436 DOI: 10.1016/j.cld.2008.03.002]
26. Mosbruger TL, Duggal P, Goedert JJ, Kirk GD, Hoots WK, Tobler LH, Busch M, Peters MG, Rosen HR, Thomas DL, Thio CL. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010; 201: 1371-1380 [PMID: 20331378 DOI: 10.1086/651606]